Drugs / ELA026
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07465835 | Feb 2026 → Jun 2028 expected | T-cell and NK-cell neoplasm | Electra Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05556863 | Oct 2021 → Nov 2023 | — | Electra Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05416307 | May 2022 → Jun 2027 expected | secondary hemophagocytic lymphohistiocytosis | Electra Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELA026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556863 ↗ |
| Action | Deplete | “designed to deplete the myeloid and T cells driving the inflammation” NCT05416307 ↗ |
| Modality | Monoclonal antibody | “fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody” NCT05416307 ↗ |
| Route | Intravenous | “ELA026 administered intravenously (IV) and subcutaneously (SC)” NCT05416307 ↗ |
| Route | Subcutaneous | “ELA026 administered intravenously (IV) and subcutaneously (SC)” NCT05416307 ↗ |